Sandbox Turky2: Difference between revisions
Jump to navigation
Jump to search
Replaced content with "{| |+ |}" |
No edit summary |
||
| Line 1: | Line 1: | ||
{| | {| border="1" | ||
|+ The table's caption | |||
| | ! Column heading 1 !! Column heading 2 !! Column heading 3 | ||
|- | |||
! Row heading 1 | |||
| Cell 2 || Cell 3 | |||
|- | |||
! Row heading A | |||
|Cell B | |||
|Cell C | |||
|} | |||
{| border="5" cellpadding="5" | |||
|+ '''GI infection''' | |||
! Pathogen !! Immunocompetent patients !! Immunocompromised patients | |||
|- align="center" | |||
|Shigella species || TMP-SMZ, 160 and 800 mg, respectively (pediatric dose, 5 and 25 mg/kg, respectively) b.i.d. 3 3 d (if susceptiblea ) or fluoroquinoloneb (e.g., 300 mg ofloxacin, 400 mg norfloxacin [186], or 500 mg ciprofloxacin b.i.d. 3 3 d) (A-I) [117–121]; nalidixic acid, 55 mg/kg/d (pediatric) or 1 g/d (adults) 3 5 d [220] or ceftriaxone [79]; azithromycin [121] || 3 7–10 d | |||
|- align="center" | |||
|Non-typhi species of Salmonella || Not recommended routinely (E-I) [59,60], but if severe or patient is !6 mo or 150 y old or has prostheses, valvular heart disease, severe atherosclerosis, malignancy, or uremia, TMP-SMZ (if susceptible) or fluoroquinoloneb as above, b.i.d. 3 5–7 d (B-III) [29, 132, 221]; ceftriaxone, 100 mg/kg/d in 1 or 2 divided doses [222 || 14 d (or longer if relapsing) | |||
|} | |} | ||
Revision as of 17:22, 29 May 2015
| Column heading 1 | Column heading 2 | Column heading 3 |
|---|---|---|
| Row heading 1 | Cell 2 | Cell 3 |
| Row heading A | Cell B | Cell C |
| Pathogen | Immunocompetent patients | Immunocompromised patients |
|---|---|---|
| Shigella species | TMP-SMZ, 160 and 800 mg, respectively (pediatric dose, 5 and 25 mg/kg, respectively) b.i.d. 3 3 d (if susceptiblea ) or fluoroquinoloneb (e.g., 300 mg ofloxacin, 400 mg norfloxacin [186], or 500 mg ciprofloxacin b.i.d. 3 3 d) (A-I) [117–121]; nalidixic acid, 55 mg/kg/d (pediatric) or 1 g/d (adults) 3 5 d [220] or ceftriaxone [79]; azithromycin [121] | 3 7–10 d |
| Non-typhi species of Salmonella | Not recommended routinely (E-I) [59,60], but if severe or patient is !6 mo or 150 y old or has prostheses, valvular heart disease, severe atherosclerosis, malignancy, or uremia, TMP-SMZ (if susceptible) or fluoroquinoloneb as above, b.i.d. 3 5–7 d (B-III) [29, 132, 221]; ceftriaxone, 100 mg/kg/d in 1 or 2 divided doses [222 | 14 d (or longer if relapsing) |